On Friday (September 27th) local time, Sanofi and Regeneron Pharmaceuticals both announced on their official websites that their heavyweight drug "Dabitol" was approved in China and the United States on the same day.
According to Sanofi China, Dabitou was approved in China before it was approved in the United States. The official websites of Sanofi and Fosun Pharma also show that although they are both on the same day, the press releases approved in China are released earlier than those approved in the United States.
Source: Sanofi official website
Specifically, the US Food and Drug Administration (FDA) has approved dupilumab injection (trade name "Dupixent") for maintenance therapy of chronic obstructive pulmonary disease (COPD), making it the first drug approved in the United States for the treatment of COPD.
It is understood that COPD is a common lung disease that can cause airflow limitation and respiratory problems, and patients' lungs may be damaged or blocked by phlegm. Symptoms include coughing, sometimes accompanied by phlegm, difficulty breathing, wheezing, and fatigue.
Smoking and air pollution are the most common causes of chronic obstructive pulmonary disease, and patients are at a higher risk of developing other health problems. According to the World Health Organization's 2023 report, COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019.
[align center] Source: World Health Organization
转播
